Final report for the Post-market Review of medicines for smoking cessation and Review outcomes

Page last updated: 22 December 2022

The final report for the Post-market Review (PMR) of medicines for smoking cessation is now available on the Review’s webpage. The final report includes the cost-effectiveness review conducted under Term of Reference 4 of the PMR. No substantive changes were made to the remaining sections of the final report from the previously published draft Review report.

The Review webpage has also been updated to include:

• The May 2022 Pharmaceutical Benefits Advisory Committee (PBAC) Minutes pertaining to the PBAC’s consideration of the Review report and Review outcomes.
• A plain language summary of the key findings for each Review Term of Reference.
• The membership of the Review Reference Group.

This information can be accessed from the Review's webpage.